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Abstract:  Chitooligosaccharides  (CHOS)  are  homo-  or  heterooligomers  of  
N-acetylglucosamine and D-glucosamine. CHOS can be produced using chitin or chitosan 
as a starting material, using enzymatic conversions, chemical methods or combinations 
thereof.  Production  of  well-defined  CHOS-mixtures,  or  even  pure  CHOS,  is  of  great 
interest since these oligosaccharides are thought to have several interesting bioactivities. 
Understanding  the  mechanisms  underlying  these  bioactivities  is  of  major  importance. 
However, so far in-depth knowledge on the mode-of-action of CHOS is scarce, one major 
reason being that most published studies are done with badly characterized heterogeneous 
mixtures of CHOS. Production of CHOS that are well-defined in terms of length, degree of 
N-acetylation,  and  sequence  is  not  straightforward.  Here  we  provide  an  overview  of 
techniques that may be used to produce and characterize reasonably well-defined CHOS 
fractions. We also present possible medical applications of CHOS, including tumor growth 
inhibition  and  inhibition  of  TH2-induced  inflammation  in  asthma,  as  well  as  use  as  a  
bone-strengthener in osteoporosis, a vector for gene delivery, an antibacterial agent, an 
antifungal agent, an anti-malaria agent, or a hemostatic agent in wound-dressings. By using 
well-defined CHOS-mixtures it will become possible to obtain a better understanding of 
the mechanisms underlying these bioactivities. 
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1. Introduction to Chitin, Chitosans and Chitooligosaccharides (CHOS) 
Chitin is a linear polysaccharide consisting of β(14) linked N-acetyl-D-glucosamine (GlcNAc; A) 
residues. It is often considered the second most abundant polysaccharide in nature, after cellulose, and 
occurs mainly as a structural component in the cell walls of fungi and yeasts and in the exoskeletons of 
insects and arthropods (e.g., crabs, lobsters and shrimps). Chitin is insoluble in water and exists mainly 
in two crystalline polymorphic forms, α and β. -Chitin consists of sheets of tightly packed alternating 
parallel and antiparallel chains [1] and is found in the exoskeleton of arthropods, in insects and in 
fungal and yeast cell walls. In β-chitin the chains are arranged in parallel [2]. β-chitin occurs less 
frequently in nature than α-chitin, but can be extracted from squid pens.  
Chitosan can be prepared from chitin by partial deacetylation, and is a heteropolymer of GlcNAc 
and  D-glucosamine  (GlcN;  D)  residues.  Unlike  chitin,  chitosan  is  soluble  in  dilute  aqueous  acid 
solutions. The name chitosan refers to a continuum of soluble polymeric chitin derivatives that can be 
described  and  classified  according  to  the  fraction  of  N-acetylated  residues  (FA)  or  degree  of  
N-acetylation (DA), the degree of polymerization (DP) or the molecular weight (MW), the molecular 
weight  distribution  (PD,  for  PolyDispersity),  and  the  pattern  of  N-acetylation  (PA)  or  sequence. 
Chitosan  exhibits  a  variety  of  interesting  physicochemical  and  biological  properties.  This,  in 
combination with its non-toxicity, biocompatibility and biodegradability, makes chitosan suitable for 
use in numerous applications in agriculture, cosmetics, water treatment and medicine [3–7].  
Chitooligosaccharides  (CHOS)  are  oligomers  prepared  from  chitosan  either  chemically  or 
enzymatically. Chitosan can be converted to CHOS by acid hydrolysis or by enzymatic hydrolysis with 
glycosyl hydrolases like chitinases or chitosanases. The FA, MW, PD and PA of the resulting CHOS-
mixture depend on the chitosan and the specificity of the enzyme used. As described below, product 
mixtures can be enriched for certain compounds by optimizing the chitosan-enzyme combination. 
There is ample literature concerning the biological effects of chitosans, but relatively little is known 
about the effects of CHOS [6,8], and the mechanisms  behind observed bioactivities are generally 
poorly understood. CHOS are primarily thought to interact with proteins that either act on chitin (e.g., 
chitinases) or that are supposed to bind to and detect chitin. When it comes to medicine, there are 
indications that CHOS may be developed as drugs against asthma [9–12], antibacterial agents [13], 
ingredients in wound-dressings [14,15] and vectors in gene-therapy [16,17]. Furthermore, according to 
the  literature,  CHOS  may  reduce  metastasis  and  tumor-growth  in  cancer  [18–20],  increase  
bone-strength in osteoporosis [21,22] and could be used to inhibit chitinases in Plasmodium parasites 
and  thereby  prevent  malaria  [23].  Several  other  potential  effects  of  CHOS  have  been  described, 
including  immune  modulatory  effects  [24],  anti-fungal  activities  [25,26]  and  a  lowering  effect  on 
serum glucose levels in diabetics [27]. In the context of this review, it should be noted that some of the 
biological effects reported for chitosan in fact may be due to CHOS, which emerge when chitosan is 
degraded by naturally occurring hydrolytic enzymes. Mar. Drugs 2010, 8                       
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So far, most of the research on bioactivities of CHOS has been done with badly defined mixtures 
containing CHOS of various FA, MW, PD and PA. Moreover, the CHOS fractions appearing in the 
literature are derived from various sources of chitosan that are not always traceable and that have been 
characterized to only a limited extent. Clearly, when using complex mixtures of CHOS in bioassays, it 
is difficult to know which molecule/molecules are causing the effects. Furthermore, reproducibility can 
be  an  issue.  All  in  all,  while  interesting  biological  activities  have  been  observed,  there  is  little 
information on the molecular properties that confer bioactivity to a particular CHOS. 
In this review we provide an overview  of some of the most promising applications of CHOS. 
Furthermore, we describe current knowledge on how well-defined mixtures of CHOS can be prepared 
and characterized. It is possible to prepare CHOS from chitosan by using different physical methods, 
like hydrothermal [28], microwave [29], ultrasonication [30] and gamma-rays [31], but these methods 
are not optimal for creating well-defined CHOS-mixtures and will not be dealt with in this review. 
Chemical methods using acid [32,33], H2O2 [34] or NaNO2 [35], can yield CHOS and one of these 
methods is described briefly below. We will, however, focus our review on the enzymatic production 
of CHOS, and on further separation and purification methods for producing well-defined mixtures. 
2. Chitosan, the Starting Material for CHOS Production 
It is possible to isolate chitosan directly from the cell walls of certain fungi, but commercially 
available  chitosans  are  usually  prepared  from  chitin  in  a  heterogeneous  deacetylation  process. 
Chitosans will in this paper be defined as proposed by Roberts [36], i.e., according to their solubility at 
acidic pH-values. This distinguishes clearly between chitins and chitosans, although some controversy 
may exist when discussing chitin oligomers (N-acetyl-CHOS) and chitosan oligomers (CHOS). To 
avoid  this  problem,  we  restrict  the  terms  chitin  and  chitosan  to  polymers  with  more  than  
100 sugar units.  
Chitosans can be prepared from chitin by two fundamentally different methods, i.e., homogeneous 
[37]  and  heterogeneous  deacetylation.  In  the  homogeneous  deacetylation  process,  the  chitin  is 
dissolved  in  an  alkali  solution  during  the  deacetylation  process  (at  low  temperature  and  using 
excessive stirring). In the heterogeneous deacetylation process, the chitin is kept insoluble in a hot 
alkali solution, meaning that this is a two-phase process. Chitosans with FA varying from 0 to about 
65%  can  be  prepared  by  homogeneous  deacetylation  of  chitin  [37].  There  is  little  controversy 
regarding the distribution (PA) of the two monomers in these chitosans, which have been found to have 
a  random  distribution  of  the  GlcNAc  and  GlcN  units,  i.e.,  according  to  Bernoullian  distribution  
[38–40]. There is, however, more controversy about the distribution of sugar units in chitosan prepared 
by heterogeneous deacetylation procedures. Weinhold et al. [41] studied the N-acetylation patterns of 
32 different chitosans of various FA, using a previously described NMR-method [39], most of them 
prepared by heterogenous deacetylation, and found a close to random distributions for all samples. 
Although this recent study indicates that the PA in chitosans prepared by heterogenous deacetylation is 
more random than previously assumed, it should be kept in mind that the NMR-method is only capable 
of determining an average distribution, meaning that certain block patterns may in fact exist.  
The annual production of chitin in nature has been estimated to approximately 10
10–10
11 tons per 
year [42]. The amounts of chitin, chitosan and their derivatives that are used/produced in industrial Mar. Drugs 2010, 8                       
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processes [43] have been estimated to be about 30 000 metric tons for chitin and about 10,000 metric 
tons for chitosan in 2007 [44]. Most of the chitin is used as raw material for the production of the 
monosaccharide GlcN, which is the number one dietary supplement in the USA, used for pain relief of 
osteoarthritis [43]. 
3. Enzymes Acting on Chitin and Chitosan 
3.1. Chitinases and chitosanases 
Enzymatic  depolymerization  of  chitin  and  chitosan  involves  chitinases  and  chitosanases, 
respectively (Figure 1). These enzymes hydrolyze the glycoside bonds between the sugars and are thus 
glycoside hydrolases (GH). Such GH are classified in the Carbohydrate-Active enZYmes database 
(CAZy) [45–48] that provides a continuously updated list of the GH families and, since a few years, 
also other families of carbohydrate-active enzymes such as glycosyl transferases and carbohydrate 
esterases. The CAZy classification is based on  the amino acid sequence, which gives very useful 
information since sequence and structure, and hence mechanism, are related. It should be noted that the 
CAZy system does not take substrate and product activities into account a priori. The same applies to 
enzyme  properties  such  as  exo-  versus  endo-binding,  processivity,  and  the  presence  of  additional 
modules that may improve substrate-binding. All these properties are not taken into account either. 
The CAZy classification is purely based on amino acid sequence similarities and, indeed, several GH 
classes  contain  enzymes  acting  on  a  variety  of  substrates.  Many  GH  enzymes  have  one  or  more 
carbohydrate  binding  domains  in  addition  to  their  catalytic  domain  (Figures  1  and  2).  These  are 
referred to as carbohydrate-binding modules (CBMs) and are also classified in the CAZy database. 
Chitinases occur in families GH18 and GH19 and both these classes almost exclusively contain 
these  enzymes.  Chitinases  have  the  unique  ability  to  hydrolyze  A-A  bonds  and  this  property 
discriminates these enzymes from chitosanases. However, as described below, chitinases are perfectly 
capable of hydrolyzing chitosan, albeit to different extents. Chitinases do not hydrolyze D-D bonds. 
Enzymes with chitosanase activity have been found in GH families 5, 7, 8, 46, 75 and 80. GH7 is a 
cellulase family and in a very few cases chitosanase activity has been detected as a side activity of 
these  enzymes.  GH5  contains  a  variety  of  enzymatic  activities,  including  chitosanases,  cellulases, 
licheninases, mannanase and xylanases. Again, chitosanase activity has been detected in only a very 
few cases, and the activity seems to be a side activity of cellulases. In GH8, enzymes annotated as 
chitosanases occur more frequently (next to e.g., cellulases and xylanases), and this family seems to 
contain a few true chitosanases [49]. The other three families, GH46, GH75 and GH80, exclusively 
contain chitosanases. Families GH75 and GH80 have only a few members and there is no structural 
and only very little functional information available for these enzymes. The best studied chitosanases, 
by far, are those belonging to family 46 [50–52] (Figure 1). 
Based  on  their  substrate  specificity  towards  chitosan,  chitosanases  have  been  classified  into 
subclasses I, II and III [53]. Chitosanases in subclass I can hydrolyze A-D and D-D linkages, subclass 
II enzymes can hydrolyze D-D linkages only, whereas subclass III enzymes can hydrolyze D-A and  
D-D linkages. Subclass I enzymes have been found in both families 46 and 75 [54,55]. In family 46, 
subclass III enzymes have also been found [52]. Mar. Drugs 2010, 8                       
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Figure 1. Structures of the enzymes discussed in detail in this review. Figure 1a and 1b 
show, respectively, ChiA and ChiB from Serratia marcescens. Figure 1c shows hevamine, 
a plant family 18 chitinase whose structure is thought to resemble the (unknown) structure 
of the catalytic domain of ChiC from Serratia marcescens. Figure 1d shows ChiG from 
Streptomyces coelicolor A3(2). Figure 1e shows CsnN174, a family 46 chitosanase from 
Streptomyces sp. N174, which, judged from sequence similarity, is highly similar to Csn88 
from  Streptomyces  coelicolor  A3(2).  The  side  chains  of  the  catalytic  acid  and  of  the 
catalytic base/nucleophile are shown. 
 
 
     
Figure 2. Schematic drawing of subsites, chitin binding domains and proposed orientation 
of polymeric substrates in ChiA and ChiB. Fn3, Fibronectin type 3 domain (substrate-
binding); CBM5, chitin binding module. Dotted lines indicate that the polymer substrates 
are much longer than shown in the figure. Reducing end sugars are shown in grey. Figure 
and  legend  are  from  Horn  et  al.  [56],  and  is  reproduced  with  permission  from  
Wiley-Blackwell. 
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3.2. Catalytic mechanism 
The hydrolysis of the glycosidic linkage is a nucleophilic substitution at the anomeric carbon, and 
can  lead  to  either  retention  or  inversion  of  the  anomeric  configuration  [57,58].  Both  hydrolysis 
reactions  take  place  through  general  acid  catalysis,  and  require  a  pair  of  carboxylic  acids  at  the 
enzyme’s  active  site.  One  carboxylic  acid  is  acting  as  a  proton  donor,  facilitating  leaving  group 
departure,  and  the  other  acts  as  a  base  (inverting  mechanism)  or  as  a  nucleophile  (retaining 
mechanism).  In  both  mechanisms,  the  position  of  the  proton  donor  is  within  hydrogen-bonding 
distance  of  the  glycosidic  oxygen.  The  inverting  mechanism  (also  called  the  single  displacement 
mechanism)  is  a  “one-step”  reaction,  where  the  protonation  of  the  glycosidic  oxygen  occurs 
simultaneously with a nucleophilic attack on the anomeric carbon by an activated water molecule. This 
water molecule is located between a carboxylic group and the anomeric carbon and it is activated by 
the carboxylic group that acts as a base. Since the water molecule approaches the anomeric carbon 
from the side of the catalytic base, this mechanism leads to inversion of the anomeric configuration. 
Chitosanases belonging to families GH46, GH75 and GH80 and family 19 chitinases use the inverting 
mechanism [45,47,49,54,59–61]. 
The retaining mechanism (also referred to as the double displacement mechanism) is a two-step 
reaction, were the first step involves the protonation of the glycosidic oxygen (by the catalytic acid) 
and a congruent nucleophilic attack on the anomeric carbon atom by the nucleophile (the second 
carboxylic  acid).  This  attack  leads  to  breakage  of  the  glycosidic  linkage  and  the  formation  of  a 
covalent linkage between the anomeric carbon and the catalytic nucleophile [62]. Subsequently, this 
intermediate is hydrolyzed by a water molecule that approaches the anomeric carbon from a position 
close  to  that  of  the  original  glycosidic  oxygen,  leading  to  retention  of  the  anomeric  
carbon configuration.  
Family 18 chitinases use a special variant of the double displacement mechanism, referred to as the 
substrate-assisted  double  displacement  mechanism.  Here,  the  carbonyl  oxygen  atom  from  the  
N-acetylgroup of the sugar bound in subsite -1 act as the nucleophile, leading to formation of an 
oxazolinium  ion  intermediate.  Because  of  this  involvement  of  the  N-acetylgroup  in  catalysis, 
productive substrate-binding of chitosan and chitosan oligomers to family 18 chitinases requires that a 
GlcNAc is bound in the -1 subsite [63–67]. 
Chitinases and chitosanases can have endo- or exo-activity, where both the endo- and exo-mode of 
action can be combined with processivity. Processive enzymes will not release the substrate after one 
cleavage, but remain associated with the substrate so that a new cleavage can take place as the polymer 
substrate slides through the substrate-binding cleft (Figure 2). Processivity is difficult to analyze when 
degrading insoluble substrates such as chitin, but can be studied when using chitosan as substrate 
[56,64,68,69].  Whereas  processivity  generally  is  considered  to  be  favorable  for  the  hydrolysis  of 
crystalline substrates, processivity has been shown to reduce enzyme efficiency towards soluble and 
more accessible polymeric substrates such as chitosan [69,70]. Thus, for the industrial production of 
CHOS, the use of non-processive enzyme variants may be beneficial in some cases. 
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3.3. Human chitinases 
Even though chitin and chitin synthases have not been found in humans, we produce two family 18 
chitinases  with  chitinolytic  activity  [71].  In  addition,  two  highly  homologous  proteins  named  
chi-lectins and a homologous protein called oviductin are expressed. These proteins lack enzymatic 
activity  while  having  retained  the  typical  features  of  family  18  enzymes,  including  carbohydrate 
binding to the active site [71].  
One  of  the  human  chitinases,  called  chitotriosidase  (HCHT),  is  synthesized  and  secreted  as  a  
50-kDa two-domain protein in human macrophages [72]. A significant portion of produced enzyme is 
routed  to  lysosomes  and  processed  into  a  39-kDa  isoform,  lacking  the  C-terminal  chitin-binding 
domain [73]. HCHT was first discovered as a marker for Gaucher disease [72], but has later been 
associated  with  several  diseases  like  malaria  [74],  fungal  infections  such  as  candidosis  [75], 
sarcoidosis [76,77], cardiovascular risk [78], coronary artery disease [79], primary prostate cancer and 
benign  prostatic  hyperplasia  [80],  nonalcoholic  steatohepatitis  [81],  multiple  sclerosis  [82],  and 
Niemann-Pick  disease  [83].  The  other  chitinase,  acidic  mammalian  chitinase  (AMCase),  is  also 
synthesized as a two-domain 50 kDa protein containing a 39 kDa N-terminal catalytic domain and a  
C-terminal chitin-binding domain. AMCase is found in the stomach [84], in tears [85], sinus mucosa 
[86], and lungs [12,84]. Chitinases play important roles in the antiparasite responses of lower life 
forms [87–89]. Both HCHT and AMCase are believed to play similar roles in the human immune 
defense system, being a part of antiparasitic responses [10,87,90].  
The two chi-lectins are associated with numerous diseases. YKL-40 (alternatively called HCgp39 or 
CHI3L1) is observed in elevated levels for patients with severe asthma [91], cardiovascular disease 
and diabetes [92], cancer [93], peritoneal endometriosis [94], morbid obesity [95], osteoarthritis [96], 
and liver fibrosis [97]. The other chi-lectin YKL-39 (or CHI3L2) has been observed up-regulated in 
osteoarthritic chondrocytes [98] and osteoarthritic cartilage [99]. The loss of hydrolytic activity in 
these chi-lectins is due to replacement of the catalytic acid (E) and the adjacent aspartic acid (D) in the 
conserved DxxDxDxE motif with Ala and Leu or Ser and Ile for YKL-40 and YKL-39, respectively. 
The chi-lectins have retained their ability to bind CHOS [100] and this may be a feature underlying 
some of the alleged biological effects of CHOS.  
3.4. Inhibition of family 18 chitinases with CHOS 
Family 18 chitinases are of particular interest, because they are abundant in nature, are crucial in the 
life cycles of numerous plague and pest organisms, and because they occur in humans themselves. 
Because  of the substrate-assisted catalytic mechanism of  GH18 enzymes,  catalysis  requires  that a 
GlcNAc is bound to the -1 subsite. CHOS that preferably bind in such a way that a GlcN ends up in the 
crucial -1 subsite will act as an inhibitor. Sugar binding to the -1 subsite leads to an energetically 
unfavorable distortion [101] which involves the N-acetylgroup [66,67] and which may amount to an 
unfavorable  ΔG  as  high  as  ~8  kcal/mol  [102].  Although  this  has  not  yet  been  substantiated  by 
experimental  data,  it  seems  plausible  that  binding  of  GlcN  in  the  -1  subsite  in  fact  could  be 
energetically  less  unfavourable  than  binding  of  a  GlcNAc.  Thus,  binding  of  a  GlcN  would  be  
non-productive, but perhaps stronger than binding of a GlcNAc. This shows that the idea of developing Mar. Drugs 2010, 8                       
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partially  deacetylated  CHOS  as  inhibitors  for  family  18  chitinases  is  worth  pursuing.  Indeed,  the 
validity of this idea has been substantiated by an early study by Peter and co-workers [103] as well as 
by more recent work [104,105]. 
For chitinase B of Serratia marcescens, the -2 subsite has a strong preference for an GlcNAc [67]. 
The oxygen atom in the acetamidogroup of the -2 sugar forms a bifurcated hydrogen bond with Trp 
403 
and Gln 
407, whereas the methyl group packs tightly in an apolar environment provided by the side 
chains of Tyr 
292 and Ile 
337. Thus, the -2 subsite of this enzyme seems optimized for strong binding of 
an GlcNAc, which is not surprising taking into account that the positive effects of binding sugars in 
subsites adjacent to the -1 subsite is needed to “pull” the -1 sugar in its distorted conformation [106]. 
Indeed, one has observed non-productive binding by a DADAA oligomer bound from subsites -3 to +2 
in chitinase B [104].  
CHOS being based on the substrate, hold a tremendous advantage in being very specific inhibitors 
towards chitinases, and hence not likely to interfere with other enzymatic systems. Moreover, the 
binding  strength  of  the  CHOS  based  inhibitor,  an  important  parameter,  can  be  tuned  simply  by 
increasing the chain length of the CHOS or by coupling additional groups to the reducing end. 
3.5. Lysozyme 
In  addition  to  its  natural  substrate,  the  glycosidic  linkage  of  certain  bacterial  cell  wall 
peptidoglycans, lysozyme may also hydrolyze chitin and chitosans [107]. In very early work, Amano 
and Ito [107] studied oligomers formed upon lysozyme degradation of an FA = 0.32 chitosan, and 
identified the fully N-acetylated trimer and tetramer together with the partially N-acetylated oligomers 
AAD, DAA, AAAD, ADAA and ADAD among the oligomeric products. Later, Vå rum et al. [108] 
studied  lysozyme  degradation  of  a  highly  N-acetylated  chitosan  (FA  =  0.65).  In  this  study,  
NMR-spectroscopy of the degradation products was used to determine the identities of the newly 
formed reducing and non-reducing ends. This methodology, which has later been used to characterize 
chitinases  (see  below),  provided  insight  into  the  cleavage  specificities  of  the  enzyme,  i.e.,  its 
preference for cleaving A-A, A-D, D-A and/or D-D linkages in chitosans. Some information on the 
identity of the nearest neighbors to the new reducing and non-reducing ends could also be obtained. 
4. CHOS Production—Enzymatic Methods 
So far, there are no robust enzymatic methods for the production of chitosan that could provide an 
alternative to the current chemical production methods. In principle, chitin deacetylases could be used 
to produce chitosan [109–113]. These enzymes hydrolyze the N-acetyl linkage and convert GlcNAc to 
GlcN. However, the insolubility and crystallinity of the chitin substrate forms a major hurdle for this 
approach. Chitin deacetylases could also be used to modify the N-acetylation pattern of CHOS, but this 
route has so far remained unexplored. 
Although  there are routes  for chemical conversion of chitosan  to CHOS [7] (see below), even 
CHOS with specific DP and PA, enzyme technology probably is the most promising approach. The 
specificity  of  chitosan-degrading  enzymes  has  traditionally  been  studied  by  extensive  enzymatic 
degradation of the polymer and subsequent isolation and characterization of the resulting oligomers. 
More recently, studies with chitinases have shown that the kinetics of the degradation reactions is such Mar. Drugs 2010, 8                       
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that product profiles change considerably during the hydrolysis reaction. Because the enzymes have 
very different binding affinities for different sequences on the substrate, reactions show multiphasic 
kinetics, and the product mixtures obtained at the end of each of these phases differ considerably. 
Another important issue is processivity; degradation processes may change during a reaction, from 
initial mainly processive hydrolysis of polymeric chains to non-processive hydrolysis of intermediate 
products as the polymeric material becomes exhausted. All in all, this means that the choice of the 
starting  chitosan,  the  choice  of  the  enzyme,  and  the  choice  of  the  processing  time  all  affect  the 
outcome of the enzymatic conversion process and that there are ample opportunities to manipulate this 
outcome  [114].  This  is  illustrated  by  several  studies  on  enzymatic  degradation  of  chitosans  
[56,60,107,114–117],  some  of  which  are  discussed  in  detail  below.  Structures  of  the  enzymes 
discussed below are shown in Figure 1, whereas Table 1 shows some key properties.  
Table 1. Some properties of the five enzymes that are specifically discussed in this review. 
Enzyme  GH 
fam 
Extra 
CBM
1 
Mechanism  Endo/Exo  Processivity  Subsite specificity 
-2  -1  +1 
Chitinases:   
ChiA  18  Yes (1)  Retaining  Endo/exo
2  Yes  A/D  A  A/D 
ChiB  18  Yes (1)  Retaining  Endo/exo
2  Yes  A/D  A  A/D 
ChiC  18  Yes (2)  Retaining  Endo  No  A/D  A  A/D 
ChiG  19  No  Inverting  Endo  No  A  A/D  A 
Chitosanase:   
Csn88  46  No  Inverting  Endo  No  D/A  D/A  D/A 
1 ChiA and ChiB are compact two domain enzymes containing an Fn3 domain and a chitin-binding domain 
classified as CBM5 in addition to their catalytic domain, respectively (Figures 1 and 2). The crystal structures 
of complete ChiA and ChiB are known (Figure 1). In ChiC, the catalytic domain is connected to an Fn3-like 
domain and a chitin-binding domain classified as CBM12 by a proline- and glycine-rich linker, which tends 
to be proteolytically cleaved in vivo. It has so far not been possible to determine the crystal structure of  
intact ChiC. 
2 It has been shown that ChiA and ChiB primarily act as endo-processive enzymes on chitosan [118]. This is 
probably also the case on chitin, although there may be more exo-activity in this case [119]. In any case, the 
endo-/exo- difference is of little relevance for enzymes that act processively. 
4.1. Degradation of chitosan by family 18 chitinases 
The degradation of chitosan by the family 18 chitinases, ChiA, ChiB and ChiC, from  Serratia 
marcescens has been studied in much detail [56,64,69,118]. Figure 3 shows the size-distribution of 
oligomers obtained upon degradation of a highly N-acetylated chitosan (FA = 0.65) to various extents 
of degradation (). For ChiA and ChiB, the product profiles obtained during the initial phase of the 
degradation show a dominance of even-numbered oligomers, which is indicative of processive action 
[56,64,68]. This product pattern is due to the fact that enzyme-ligand complexes where there is a GlcN 
bound  to  the  -1  subsite  is  not  productive  (in  the  case  of  family  18  chitinases).  If  the  enzyme  is 
processive, the enzyme will slide by two sugar units at the time, until a productive complex is formed Mar. Drugs 2010, 8                       
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[the primary condition being that there is an GlcNAc bound in the -1 subsite (see Sø rbotten et al. [64] 
and Eijsink et al. [68] for a more detailed discussion)]. Consequently, while the first product of an 
enzyme-substrate association may have any length, every subsequent product will be even-numbered. 
In the case of chitin, all these products would be dimers; in the case of chitosan, these products may be 
longer  even-numbered  oligomers.  Later  during  the  reaction,  the  dominance  of  even-numbered 
oligomers disappears because there are no longer substrate molecules left and the enzyme is primarily 
involved in rebinding and further cleavage of oligomers from the preceding processive phase (see 
Figure  3).  For  example,  an  oligomer  such  as  ADADAA  that  could  emerge  during  processive 
degradation by ChiB can be converted by this same enzyme to ADA and DAA upon rebinding in a 
mode that was not explored during the processive phase, where the substrate moves by two sugars at 
the time (see Horn et al. [56] and Eijsink et al. [68] for a more extensive discussion and explanation). 
Figure  3.  Degradation  of  chitosan  (FA  0.65)  by  ChiA,  ChiB  and  ChiC  from  Serratia 
marcescens. The pictures show chromatograms from size-exclusion chromatography. The 
peaks  are  marked  by  numbers  which  indicate  the  lengths  (DP)  of  the  oligomers  they 
contain, or, in the case of peaks containing only one known compound, by the sequence of 
the oligomer. The annotation of the peaks is based on the use of standard samples, as well 
as  NMR  analyses.  The  -values  denote  the  degree  of  scission  [full  conversion  of  the 
chitosan to dimers only (DPn = 2) would give an α = 0.5 (α = 1/DPn)]. The lower panels 
represent the maximum obtainable -values. Undegraded chitosan and fragments with a 
DP > 40 elute in the void volume of the column. The figure is from Horn et al. [56], and is 
reproduced with permission from Wiley-Blackwell. Additional product profiles at very low 
  for  ChiA  and  ChiB  that  clearly  reveal  processivity  have  been  published  in  
Sikorski et al. [118]. 
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Figure 3 shows a totally different product pattern for ChiC that is characteristic for an endo-acting, 
non-processive enzyme. ChiC converts chitosan to a continuum of oligomers of different sizes and the 
polymer peak disappears early in the degradation reaction. Also, there is initially no accumulation of 
dimers or other even numbered oligomers. This all indicates that ChiC attacks the polymeric substrate 
chains in random positions, without processivity. Indeed, this “endo” activity could be confirmed by 
viscosity measurements during the hydrolysis reaction [118]. The contrast with ChiA and ChiB is 
perhaps best illustrated by the void peak, which disappears much more slowly in the case of processive 
enzymes. These latter enzymes perform many cuts per chain instead of a few cuts in every chain as in 
the case of ChiC. 
Analysis of the sequences of the products (Table 2) showed considerable differences between the 
enzymes as well as differences over the time course of the degradation reactions. In all three enzymes, 
productive binding requires a GlcNAc in subsite -1, explaining why all products have a GlcNAc at 
their reducing ends. The enzymes did not have any detectable preferences for GlcNAc versus GlcN in 
the  +1  subsite,  and  this  is  reflected  in  the  oligomers  having  both  N-acetylated  and  deacetylated  
non-reducing ends. All three chitinases showed a strong, but not absolute, preference for GlcNAc in 
subsite -2, meaning that oligomers preferentially have an N-acetylated unit next to the reducing end. 
The kinetics of the reaction with ChiB illustrate this (Figure 4; Table 2): in the initial rapid phase of the 
reaction almost all oligomeric producs have –AA at their reducing ends; during the second, much 
slower phase, oligomeric products ending at –DA appear to a larger extent [56, 64]. The preference for 
a GlcNAc in subsite -2 was strongest and in fact almost absolute for ChiC; all oligomeric products end 
with –AA, at any point during the reaction (Table 2). 
Table 2. Composition of dimer, trimer and tetramer fractions at different -values during 
degradation  of  chitosan  (FA  =  0.65)  by  ChiA,  B  and  C.  Data  from  Horn  et  al.  [56]. 
Reproduced with permission from Wiley-Blackwell. 
Enzyme    Dimer  Trimer  Tetramer 
ChiA 
0.15 
81% AA 
19% DA 
81% DAA 
19% ADA 
100% -AA 
0.35 
64% AA 
36% DA 
51% DAA 
28% ADA 
21% DDA 
56% -AA 
44% -DA 
ChiB 
0.11 
86% AA 
14% DA 
71% DDA 
29% AAA 
100% -AA 
 
0.38 
66% AA 
34% DA 
95% DAA 
3% DDA 
2% ADA 
75% -AA 
25% -DA 
 
ChiC 
0.20 
100% AA  66% DAA 
34% AAA 
100% -AA 
0.38 
81% AA 
19% DA 
100% DAA  100% -AA 
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Figure 4. Time course of the degradation of a chitosan with FA 0.65 by ChiB from Serratia 
marcescens. The graph shows the degree of scission (α) as a function of time; the biphasic 
kinetics is clearly visible. The slow phase continues until α reaches a value of about 0.37. 
Figure from Sø rbotten et al. [64]. Reproduced with permission from Wiley-Blackwell. 
 
Figure  5.  Size-distribution of oligomers after extended hydrolysis of various chitosans 
with  ChiB  from  Serratia  marcescens.  The  pictures  show  chromatograms  revealing  the 
size-distribution of oligomers obtained upon extended hydrolysis of chitosans with FA of 
0.65, 0.50, 0.32 and 0.13 to α-values (corresponding DPn-values in brackets) of 0.37 (2.7), 
0.34  (2.9),  0.22  (4.5)  and  0.11  (9.5),  respectively.  Figure  from  Sø rbotten  et  al.  [64]. 
Reproduced with permission from Wiley-Blackwell. 
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Figure 5 shows how the outcome in terms of the length distribution of products can be manipulated 
by  varying  the  FA  of  the  chitosan.  Obviously,  since  we  are  working  with  chitinases  with  clear 
preferences for GlcNAcs at certain positions in the substrate, the products get longer as the FA goes 
down. It is quite remarkable that a chitinase such as ChiB works well on chitosans with FA close to 
only 10%.  
Sikorski et al. [114,118] have produced a model for the degradation of different chitosans with 
ChiB, which is capable of accurately predicting the outcome of hydrolysis reactions in terms of the 
length distributions of the products at varying . This model can be used to predict how reactions need 
to be set up in order to maximize the production of CHOS of certain lengths (Figure 6). 
Figure 6. 2D profiles showing the predicted outcome of chitosan hydrolysis with ChiB 
from Serratia marcescens. The X-axis shows the degree of scission, α, and the Y-axis 
shows the FA of the starting chitosan. The predicted amount of a particular product at 
specific α - FA combinations is indicated by color (the amounts of oligomers are expressed 
as % of the total mass of the polymer in the hydrolysis reaction and color coded as defined 
in  the  inserts).  These  profiles  allow  for  selection  of  optimal  reaction  and  substrate 
parameters for efficient production of oligomers with desired lengths. For example, high 
yields of octamer could be obtained if chitosan with FA 0.4 is hydrolyzed to α = 0.18 (the 
arrow  indicates  the  maximum  level  of  octamers).  For  example,  for  the  octamer,  at 
maximum yield conditions, approximately 8% of the polymer is expected to be converted 
to octamers. Figure taken from Sikorski et al. [114], and reproduced with permission from 
Wiley-Blackwell. 
 
4.2. Degradation of chitosan by family 19 chitinases 
ChiG, a bacterial family 19 chitinase from Streptomyces coelicolor A3(2), produces quite different 
CHOS as compared to the family 18 chitinases, reflecting the very different binding preferences in the 
active  sites  of  the  enzymes  [115].  Since  ChiG,  which  operates  according  to  a  non-processive  Mar. Drugs 2010, 8                       
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endo-mode of action (Figure 7), uses the inverting mechanism, there is no absolute requirement for 
GlcNAc in subsite -1. This means that the reducing ends of the oligomeric products could be both  
N-acetylated and deacetylated, as was indeed observed. The non-reducing ends of the oligomers were 
found to be exclusively N-acetylated, and the sugar units in the neighboring position to reducing ends 
were also found to be exclusively N-acetylated. Thus, ChiG has an absolute preference for a GlcNAc 
in subsites -2 and +1. The enzyme also has considerable preference for GlcNAc in -1 and kinetics were 
clearly  biphasic:  In  the  first  fast  phase  cleavage  occurred  in  A-A
↓A  sequences,  whereas  A-D
↓A 
sequences were cleaved in the slower second phase [115]. So, while the chromatograms of Figure 7 
may look somewhat similar to the chromatogram for the family 18 enzyme ChiC in Figure 3, the 
sequences of the produced oligomers show considerable differences, which may affect bioactivity. 
More generally, it is clear that ChiG will yield oligomers of different PA as compared to those obtained 
by ChiA, ChiB and ChiC. For example, degrading a chitosan with FA = 0.65 with ChiB and ChiG 
gives the trimers DAA and AAD, respectively [64,115]. 
Figure  7.  Size-distribution  of  oligomers  emerging  during  hydrolysis  of  chitosan  with  
FA 0.64 by ChiG from Streptomyces coelicolor A3(2). See legend to Figure 3 for further 
explanation. Figure from Heggset et al. [115]. Reproduced with permission from American 
Chemical Society. 
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Figure 7. Cont. 
 
Figure 8 shows that varying the FA of the chitosan had a major effect on the size distribution of the 
products  and  the  extent  of  cleavage.  Interestingly,  ChiG  efficiency  is  much  more  sensitive  for 
deacetylation than the efficiency of ChiB (compare Figure 8 with Figure 5). 
Other studies on the degradation of chitosan with family 19 chitinases confirm the findings for 
ChiG. In one study, the family 19 chitinase ChiC from Streptomyces griseus HUT 6037 was used to 
(extensively) degrade a chitosan with a degree of N-acetylation of 47% and the products were isolated 
and characterized [116]. The identities of the isolated CHOS were AD, AAD, ADAD, ADDAA and 
AADDAA, and it was concluded that this enzyme has an absolute specificity for N-acetylated units in 
the -2 and +1 subsites, in agreement with the results for ChiG from Streptomyces coelicolor. A family 
19 chitinase from rice [117] has been found to operate according to a non-processive endo-mode of 
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action,  with  strong  preferences  for  N-acetylated  units  in  subsites  -2  and  +1,  and  with  less  strong 
preference for N-acetylated units in the -1 subsite.  
Figure  8.  Size-distribution of oligomers after extended hydrolysis of various chitosans 
with ChiG from Streptomyces coelicolor A3(2). The chitosans with FA of 0.13, 0.32, 0.50, 
and 0.64 were degraded to maximum -values of 0.04, 0.12, 0.23, and 0.33, respectively. 
Peaks  are  labeled  as  in  Figure  3.  Figure  from  Heggset  et  al.  [115].  Reproduced  with 
permission from American Chemical Society. 
  
4.3. Degradation of chitosan by family 46 chitosanases 
The GH 46 family of chitosanases comprises enzymes classified as subclass I (cleaving A-D and  
D-D linkages) [60] as well as subclass III (cleaving D-A and D-D linkages) [120].  
In an early study, a chitosan with FA = 0.25–0.35 was extensively degraded with CsnN174 from 
Streptomyces sp. N174 and the oligomeric products were isolated and characterized. In addition to the 
fully deacetylated oligomers D, DD and DDD, several hetero-oligomers were identified (the dimer 
DA, the trimers DDA and DAA, the tetramers DDAA and DAAA and the pentamer DDAAA) [60]. 
These  results  suggest  that  CsnN174  has  a  high  specificity  for  a  GlcN  in  the  +1  subsite  (new  
non-reducing ends), whereas both GlcNAc and GlcN seem to be acceptable in the -1 subsite (new 
reducing ends). Further insight  into the properties  of CsnN174 would require studies  of oligomer 
production over time, as well as studies using chitosans of varying FA.  
Recent  work  in  our  own  laboratories  on  a  family  46  chitosanase,  Csn88,  from  Streptomyces 
coelicolor has shown that this enzyme is capable of degrading chitosans with varying FA, producing 
oligomers  with  both  N-acetylated  and  deacetylated  reducing  ends  [121]. 
1H  NMR  spectroscopy 
analysis  showed  that  when  the  new  reducing  ends  were  N-acetylated,  the  sugar  binding  in  the 
neighbouring position (i.e., binding in subsite -2) always was deacetylated. However, in oligomers Mar. Drugs 2010, 8                       
 
 
1498 
with deacetylated sugars at the new reducing end, both N-acetylated and deacetylated sugar occurred in 
the neighbouring position (revealed by mass spectrometry). The identity of the new non-reducing ends 
was studied using 
13C NMR spectroscopy and this analysis showed that initial products exclusively 
had deacetylated non-reducing ends, whereas N-acetylated non-reducing ends appeared later during the 
reaction. All in all, these preliminary data indicate that Csn88 can cleave D-A, A-D and D-D linkages. 
As  expected  maximum    values  were  high,  for  example  0.59  for  a  highly  deacetylated  chitosan  
(FA 0.008) and 0.44 for a FA 0.32 chitosan. 
4.4. Degradation of chitosan by unspecific enzymes 
Several  authors  have  employed  unspecific  enzymes  such  as  papaine  and  cellulases  to  degrade 
chitosans (e.g., [122–124]). Since the enzyme preparations used tend to be rather crude and derived 
from sources (fungi, plants) that are known to produce chitinolytic enzymes, there remains some doubt 
concerning  which  enzymes  actually  catalyze  the  hydrolysis  reactions.  However,  for  the  practical 
purpose of producing CHOS, the use of (cheap) unspecific enzymes may be quite useful. 
5. CHOS Production—Chemical Methods 
5.1. Acid hydrolysis of chitosan 
Of  chemical  methods  for  hydrolysis  of  chitosan  [32–35],  acid  hydrolysis  is  probably  the  best 
known. Early studies on acid hydrolysis of chitosans had shown that it is possible to convert fully 
deacetylated chitosan to CHOS in concentrated hydrochloric acid [32]. In later studies [33], using a 
variety of chitosans, the acid-catalyzed degradation rates of chitosans were shown to depend on FA, 
and  the  initial  degradation  rate  constant  was  found  to  increase  in  direct  proportion  to  FA.  Acid 
hydrolysis was found to be highly specific to cleavage of A-A and A-D glycosidic linkages, which 
were hydrolyzed with two to three orders of magnitude higher rates than the D-D and D-A linkages. 
This preference is probably due to a combination of two factors: (1) the presence of a positively 
charged amino group (as in GlcN) close to the glycosidic linkage is inhibitory, and (2) the presence of 
an acetamidogroup (as in GlcNAc) close to the glycosidic linkage may yield some degree of substrate-
assistance to the hydrolytic mechanism. In the same study it was shown that the rate of deacetylation 
was less than one-tenth of the rate of depolymerization in concentrated acid, whereas the two rates 
were found to be equal in dilute acid. It was suggested that this is due to these two processes having 
different reaction mechanisms with different rate-limiting steps [33].  
5.2. Chemical synthesis of CHOS 
Chemical synthesis of CHOS requires multiple protection and deprotection steps, and is today not a 
routine procedure. Chemical synthesis of CHOS gives rise to pure compounds, but most methods 
existing today are time consuming and require extensive use of organic solvents and/or are not capable 
of producing anything else than homo-oligomers. There are in fact only a few examples of chemically 
synthesized CHOS in the literature. Kuyama et al. [125] performed synthesis of fully deacetylated 
chitosan dodecamers starting with glucosamine monomers using phthalimido as the amino protective 
group.  Aly  et  al.  [126]  reported  a  method  for  synthesis  of  fully  N-acetylated  CHOS  from  GlcN Mar. Drugs 2010, 8                       
 
 
1499 
monomers  using dimethylmaleoyl as an amino protective group for synthesis of chitotetraose and 
chitohexaose. Removal of the amino protective group and N-acetylation was performed in a one-pot 
reaction to give the desired products [127]. In principle it would be possible to combine the use of 
these two described protection methods to synthesize partly deacetylated CHOS, but this has so far not 
been reported (to our knowledge). 
Trombotto  et al. [128]  have reported a method for chemical preparation of partly deacetylated 
CHOS from fully deacetylated high molecular weight chitosan. The starting chitosan was partially 
depolymerized using HCl to produce fully deacetylated oligomers that were fractionated by selective 
precipitation and ultrafiltration to yield a mixture of DP 2–DP 12. The oligomers were then partly  
N-acetylated using stochiometric amounts of acetic anhydride to reach the decided FA. In this way, 
CHOS fractions of DP between 2 and 12 were successfully prepared. The drawback of this method, as 
for the enzymatic preparation of CHOS, is the heterogeneity of the prepared CHOS. 
In an early study, Letzel et al. [103] used a similar approach: chitosan with FA 0.02 was hydrolyzed 
with HCl, oligomers were separated by DP using gel permeation chromatography and the resulting 
CHOS fractions were N-acetylated using substoichiometric amounts of acetic anhydride to control the 
FA. Interestingly, some of the fractions produced in this study inhibited the family 18 chitinase ChiB 
from Serratia marcescens. 
In principle, chemoenzymatic synthesis provides opportunities to produce pure CHOS of defined 
DP, FA and PA without the use of extensive protection of the functional groups at the sugar unit. So far 
this has been done by allowing an oxazoline, imitating the intermediate of chitin hydrolysis, to act as a 
glycosyl donor in an enzyme-catalyzed reaction where another GlcN/GlcNAc unit acts as a glycosyl 
acceptor [129]. By using oxazoline oligomeric building blocks of specific DP, FA, and PA, longer 
specific CHOS can be made using this approach. The main disadvantage using the chemo-enzymatic 
approach is that the product is necessarily also a substrate for the enzyme, which can result in poor 
yields. To avoid this problem, modified enzymes with reduced hydrolytic activity may be employed. 
The enzyme modifications would need to be aimed at reducing hydrolytic power, while increasing 
binding strength for the glycosyl donor in the glycon subsites [130]. 
6. Purification and Characterization of CHOS 
CHOS produced enzymatically or chemically normally consist of a mixture of oligomers differing 
in DP, FA and PA. Several techniques for separation and purification of CHOS have been reported, like 
gelfiltration  [64],  ultrafiltration  [131],  and  ion  exchange  [132]  and  metal  affinity  [133] 
chromatography. Often, such techniques need to be applied in combination to obtain homogeneous 
CHOS fractions. Despite some successful studies, the production of pure CHOS fractions is generally 
a time consuming and challenging task.  
Preparative  separation  of  CHOS  is  most  commonly  based  on  size,  through  size  exclusion 
chromatography  (SEC).  Recently,  good  methods  for  the  separation  of  oligomers  up  to  DP  40 
(individual oligomers up to DP 20) have been described [64], as illustrated by Figure 3, 5, 7 and 8. The 
SEC system used for producing the data displayed in this review is based on Superdex
TM 30 (GE 
Healthcare) columns that are coupled in series. The oligomers are detected using an online refractive Mar. Drugs 2010, 8                       
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index  detector.  This  system  allows  separation  of  CHOS  with  similar  DP  values  ranging  from 
approximately DP 2 to DP 20, independently of FA and PA [64]. 
Further  separation  of  CHOS  can  be  achieved  using  cation-exchange  chromatography,  because 
protonated amino groups on the deacetylated sugars interact with the ion-exchange material. With this 
method CHOS of identical DP will be separated based on the number of deacetylated units [132]. A 
further partial separation of isobaric CHOS (identical FA, different PA) may be achieved using strong 
cation exchange chromatography. Although, the latter separations are promising and useful, baseline 
separation of isobaric CHOS has so far not been achieved [132]. In an alternative strategy, metal 
affinity chromatography has been successfully used for separation of shorter CHOS. CHOS have a 
strong affinity for Cu
2+, and using copper as a chelating agent gives separation up to 90% of fully 
deacetylated CHOS of DP 3 and higher [133]. This has not been reported for N-acetylated mixtures  
of CHOS.  
In order to characterize CHOS in terms of DP, FA and PA, several techniques have been applied, 
primarily nuclear magnetic resonance (NMR) and mass spectrometry. Using NMR, it is possible to 
determine  FA  in  a  chitosan  or  CHOS  sample  and  to  (partially)  identify  the  PA  in  shorter  CHOS 
depending on the complexity of the oligomer mixture. Resonances detected using NMR reveal that the 
H-1 resonance of a reducing unit is sensitive to its nearest neighbor, making it possible to (partially) 
determine the PA of an oligomer [64]. In addition, the PA of dimers and trimers can be determined 
using  NMR.  The  identity  of  the  non-reducing  end  unit  of  an  oligomer  can  be  determined  using  
13C NMR, which in some instances also may reveal the identity of its nearest neighbor [108]. 
Modern mass spectrometry provides excellent tools for the identification of the DP and FA of CHOS 
[104,134]. In 1997 Okafo et al. [135] reported a reductive amination of CHOS using 2-aminoacridone 
(AMAC), which is useful for tagging of the reducing end. Building on this labeling technique, Bahrke 
et  al.  [134]  developed  a  method  for  sequencing  of  CHOS  up  to  DP  12  using  reducing  end 
derivatization  with  AMAC.  Starting  with  CHOS  fractions  of  homogeneous  DP  they  used  matrix-
assisted  laser  desorption  ionization  (MALDI)  time-of-flight  (TOF)  postsource  decay  (PSD)  mass 
spectrometry (MS) for sequence determination. Reducing end derivatization of CHOS using AMAC 
favors formation of Y-type ions, meaning that sugars are only cleaved after the oxygen in the β(14) 
linkage  from the reducing end.  Consequently, interpretation of the resulting  mass  spectra is quite 
straightforward. It should be noted though that the method has limitations when applied to mixtures. 
In  a  later  study  from  the  same  group  [132],  a  second  method  for  reductive  amination,  using  
3-(acetylamino)-6-aminoacridine,  was  adopted.  Combined  detection  and  fragmentation  of  isobaric 
CHOS  using  MALDI  iontrap  MS
n  was  reported.  The  described  technique  makes  it  possible  to 
simultaneously determine sequence and quantity of CHOS of identical DP but different FA and PA in 
an isobaric CHOS mixture. 
7. Applications of CHOS  
Literature contains numerous papers reporting a remarkably wide range of biological activities of 
CHOS. As discussed above, the molecular mechanisms behind these bioactivities are mostly unknown 
and so is the exact nature of the bioactive component. Many activities have been reported only once or 
twice,  providing  insufficient  basis  to  make  general  conclusions  about  the  applicability  of  CHOS. Mar. Drugs 2010, 8                       
 
 
1501 
Below, we discuss  a selection of studies that report such bioactivities,  with  focus on studies that 
contain some discussion of the molecular mechanisms involved. 
7.1. Tumor growth inhibition 
It  has  been  known  since  the  1970s  that  CHOS  have  anti-tumor  effects  [18],  and  there  is  also 
evidence  for  positive  effects  of  CHOS  in  reducing  metastasis  from  tumors  [19,20].  It  was  first 
suggested that the anti-tumor activity was due to the cationic properties of CHOS [18]. Later, MW also 
was proposed to play a major role [136]. Maeda and Kimura [137] found that CHOS enhanced the 
natural killer activity in intestinal intraepitelial lymphocytes at the same time as they reduced tumor 
growth in mice, and suggested that this CHOS-activation of intestinal immune functions could be 
useful in treating tumors. 
There are indications that apoptosis is involved in the tumor-reducing effects of CHOS. Harish 
Prashanth  and  Tharanathan  [138]  discovered  that  DNA  from  Ehrlich  ascites  tumor  cells  was 
fragmented after incubation with CHOS, an indication of apoptosis. CHOS have also been shown to 
induce apoptosis of human hepatocellular carcinoma cell via upregulation of the pro-apoptotic protein 
Bax [139]. 
In recent years, the hypothesis that the anti-tumor effects of CHOS are related to their inhibitory 
effects on angiogenesis has received some attention [138,140,141]. Angiogenesis is the formation of 
new capillary blood vessels from already existing blood vessels. This process is important for tumor 
formation, since tumor growth and metastasis require angiogenesis when the tumor reaches a certain 
size.  Xiong  et  al.  [142]  compared  effects  of  dimers  to  hexamers  of  fully  deacetylated  CHOS  on 
angiogenesis and found that the hexamers were the most effective inhibitors, whereas Wang et al. 
[140]  showed  that  N-acetylated  CHOS  were  more  effective  in  preventing  angiogenesis  than  fully 
deacetylated CHOS, both in vitro and in vivo. 
7.2. Asthma  
AMCase is induced during TH2 inflammation through an interleukin (IL)-13 dependent mechanism 
and has been demonstrated to be heavily over-expressed in human asthmatic tissue [10,12]. Inhibition 
of the AMCase with the well known chitinase inhibitor allosamidin reduced the inflammation [12]. 
The fact that chitinases are a factor in host antiparasite responses and in asthmatic TH2 inflammation 
led to the hypothesis that asthma may be a parasite-independent antiparasite response [10], which 
again suggests that inhibition of AMCase is a potential target for asthma therapy [9–12]. It has been 
shown that partially deacetylated CHOS can function as inhibitors of family 18 chitinases [103–105]. 
There is therefore a great potential for CHOS as an anti-inflammatory drug in patients with asthma. 
For a more detailed description of this and related topics, see the review by Muzzarelli in this special 
issue of Marine Drugs [143]. 
7.3. Increased bone strength  
Mesenchymal  stem  cells  from  the  bone  marrow  are  able  to  differentiate  into  chondrocytes 
(cartilage),  adipocytes  (fat)  and  osteoblasts  (bone).  Osteoblasts  produce  osteoid;  which  is  further Mar. Drugs 2010, 8                       
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mineralized  to  produce  the  bone  matrix.  Bone-tissue  is  mainly  composed  of  bone  matrix  and 
osteoblasts. Chitosan and CHOS are known to increase the differentiation of mesenchymal stem cells 
to osteoblasts and to consequently facilitate the formation of bone-tissue [21,22].  
The mineralization process and bone strength are dependent on Ca
2+, which helps to support the 
structure. There is evidence that CHOS increase calcium-deposition in bone [22,144,145]. Jung et al. 
[144] found that CHOS could efficiently inhibit the formation of insoluble calcium-phosphate salts and 
consequently increase Ca
2+ bioavailability and bone strength. They also found that CHOS (<5 kDa) 
gave  increased  calcium  retention  and  decreased  bone  turnover  in  a  rat  osteoporosis  model.  This 
indicates that CHOS may have beneficial effects as a calcium fortifier in conditions of Ca
2+ deficiency, 
such as in osteoporosis.  
7.4. CHOS in gene therapy 
Chitosans have been successfully used as vectors for delivery of genes (gene therapy) since the first 
report about 15 years ago [146,147]. Chitosan forms stable complexes with plasmid DNA and can be 
used  as  a  vector  for  the  administration  of  genes  to  mucosal  tissues  such  as  the  lungs  [148]  and 
intestinal epithelium [149,150]. There are, however, certain drawbacks connected to the use of high 
molecular weight chitosans because of the low solubility at physiological pH, the high viscosity and 
the fact that the chitosan complexes often tend to form aggregates. By using CHOS instead of chitosan 
these drawbacks may be overcome [16]. Kö ping-Hö ggå rd et al. [16] showed that fully deacetylated 
CHOS (DP 24) formed stable complexes with plasmid DNA, and in vitro and in vivo experiments 
proved that these CHOS were effective vectors for delivery of genes [16,17]. It has been speculated 
that a delicate balance between the stability of the CHOS-DNA-complexes at lower pH-values (around 
pH 6) and their instability at higher pH-values (above pH 7) could be the reason for their efficiency 
[151]. This has recently been confirmed in detailed studies of how chitosan chemistry can be used to 
create an optimal balance between the stability of the complexes and their unpacking [152].  
7.5. Prevention of bacterial adhesion to human cells 
Some pathogens can initiate disease in humans by using carbohydrate binding proteins (lectins) to 
attach  to  complementary  membrane-bound  oligosaccharides  on  host  cells  [153,154].  Observed 
antibacterial and anti-infective effects of CHOS [13] are thought to be due to their ability to bind to the 
lectins on human pathogens and, consequently, prevent adhesion to human cells. A priori, one would 
expect the sequence of GlcNAc and GlcN units in CHOS to be important for binding affinity, and for 
ensuring selectivity for pathogens (i.e., the CHOS should preferably not bind to lectins of the normal 
bacterial  flora).  In  a  recent  study,  it  was  shown  that  a  mixture  of  97%  deacetylated  tetramers 
significantly inhibited adhesion of certain enteropathogenic Escherichia coli strains to human colon 
adenocarcinoma epithelial (HT29) cells in tissue culture, whereas the binding of other E. coli strains 
was  not  inhibited  [13].  Since  pathogens  vary  in  terms  of  their  lectins,  identification  of  both  the  
target-lectins and the possible complementary CHOS are important when pursuing this application 
route of CHOS. 
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7.6. CHOS as a chitinase-inhibitor for preventing malaria 
Malaria is caused by several species of the parasite Plasmodium. P. falciparum causes the most 
serious forms of malaria in humans, whereas P. vivax, P. ovale and P. malarie give a milder disease 
that is not generally fatal [155]. Each year, 350–500 million cases of malaria occur worldwide, and 
over one million people die, most of them young children in sub-Saharan Africa. There is no vaccine 
available, and the identification of molecular targets for vaccine development is of great importance. 
Anopheles mosquitoes transmit the malaria-parasite from one infected person to another and the most 
important control strategy for malaria today is to interfere with different stages in the life cycle of the 
Plasmodium parasite.  
During its life cycle, the Plasmodium parasite must be capable of penetrating the chitin-containing 
periotrophic  matrix  surrounding  the  mosquito  midgut,  to  make  the  mosquito  infective.  To  do  so, 
Plasmodium  species  secrete  family  18  chitinases  capable  of  degrading  the  periotrophic  matrix 
[23,156–160]. The P. falciparum chitinase (PfCHT1), the P. vivax chitinase (PvCHT1) and the P. 
gallinaceum  chitinase  (PgCHT1)  have  been  characterized  [161–163].  P.  gallinaceum  is  the  only 
malaria parasite species where more than one chitinase gene has been identified, and PgCHT1 and 
PgCHT2 are both family 18 chitinases. One approach to vector control might be inhibition of the 
secreted Plasmodium chitinases by chitinase inhibitors that are taken up by the mosquito via the blood 
meal [23,156–160]. Several studies have convincingly shown that inhibition of Plasmodium chitinases 
indeed reduces infectivity [23,163,164]. CHOS may perhaps be developed as nontoxic, inexpensive 
small-molecule inhibitors of these chitinases. 
7.7. Applications of chitosan/CHOS in wound-dressings  
The use of chitosan in wound dressings has been explored to a certain extent and positive effects 
have been documented in several studies [14,165–169]. Similar positive effects have been documented 
for CHOS, which were shown to accelerate the wound healing process [14,15]. It is quite likely that 
chitosan is converted to CHOS by naturally occurring enzymes and that the activity observed for 
chitosan might in fact be caused by CHOS. It may thus be advantageous to use CHOS in wound 
dressings to get a more immediate effect. 
CHOS are thought to accelerate wound healing by enhancing the functions of inflammatory and 
repairing cells [170–172]. For example, it has been shown that subcutaneous injection of hexamers of 
CHOS enhanced migration of polymorphonuclear cells in dogs [171]. Hexamers of N-acetylated and 
fully  deacetylated  CHOS  were  shown  to  induce  persistent  release  of  IL-8,  a  potent  activator  and 
chemoattractant of polymorphonuclear cells, from fibroblasts from rats in vitro [170]. It must be noted 
that most authors ascribe the beneficial effect of longer CHOS and (polymeric) chitosan on wound 
healing to the ability of these compounds to form biocompatible ordered tissue-like structures (see 
[167] and references therein). 
Hemostatic  effects  may  also  contribute  to  the  beneficial  effects  of  chitosan/CHOS  in  wound 
dressings. Chitosan enhances platelet adhesion and aggregation [165,173] and increases the release of 
the platelet derived growth factor-AB (PDGF-AB) and the transforming growth factor-β1 (TGF-β1) 
from platelets in canine blood [173]. These two factors retract inflammatory cells which are thought to Mar. Drugs 2010, 8                       
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be  important  in  wound  healing.  Chitosan  also  has  the  ability  of  causing  erythrocytes  to 
aggregate [169]. 
Minagawa et al. [166] compared wound break strength and the increase in collagenase activity in 
wounds in rats after exposure to monomers, oligomers and polymers of the chitin-group (GlcNAc/ 
N-acetylated CHOS/chitin) and the chitosan-group (GlcN/fully deacetylated CHOS/chitosan). They 
found that all six compounds increased both the wound break strength and the collagenase activity. 
Overall,  the  non-acetylated  compounds  were  most  effective  compared  to  the  corresponding  
N-acetylated compounds. The oligomers of fully deacetylated CHOS were most effective for wound 
break strength and GlcN gave the highest activity of collagenase. The enzyme collagenase is produced 
mainly  by  fibroblasts  and  inflammatory  cells  and  its  activity  is  related  to  remodeling  in  wound  
healing [174]. 
7.8. Antifungal effects 
The antifungal activity of chitosan was discovered already in 1979 [175], and has been utilized to 
inhibit fungal growth in crops [176]. The antifungal potential of CHOS has to a lesser extent been 
investigated.  In  1984  Kendra  and  Hadwiger  [177]  tested  the  antifungal  activity  of  monomers–
heptamers of deacetylated CHOS on Fusarium solani, which is infectious to pea crops, and found that 
the heptamer was most effective.  
Subsequent research has revealed that longer oligomers of CHOS (also called low molecular weight 
chitosan, LMWC) are more effective. LMWC (4.6 kDa, average DP of 23) shows antifungal activity 
against Candida krusei and inhibits spore germination in Fusarium oxysporum [178]. Seyfarth et al. 
[26]  found  antifungal  effects  of  LMWC  on  different  Candida  species.  Both  DP  and  FA  of  the 
chitosan/CHOS are of great importance for the antifungal potential and LMWC with low FA so far 
seems to be the most promising type of compound [179]. 
The anti-fungal effect of LMWC seems to be caused by its interaction with lipids in the plasma 
membrane, leading to morphological changes and cell surface disruptions [180,181]. The composition 
of the fungal plasma-membrane seems to be important for the sensitivity against chitosan, and a higher 
content of polyunsaturated fatty acids makes the fungi more sensitive [182]. 
From literature studies, as well as from own unpublished work on non-medical use of LMWC as 
anti-fungals, it is clear that LMWC indeed have a considerable potential in this area. This is a good 
reason for giving the application of LMWC, to combat fungal infections in humans, more research 
attention than it has received so far. 
8. Concluding Remarks and Future Perspectives 
Despite major progress in the past decade, the production of pure CHOS with defined DP, FA and 
PA is still a challenge. However, it is now fully possible to carry out controlled and reasonably well 
understood enzymatic production processes that yield CHOS preparations that are enriched for certain 
known compounds. The outcome of such processes can be controlled by controlling the enzyme, the 
starting chitosan (primarily FA), and the extent to which the degradation reaction is allowed to develop. 
Further refinement of the production step may be achieved by using engineered enzymes with changed Mar. Drugs 2010, 8                       
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binding preferences in one or more of their subsites and by carrying out specific deacetylation steps 
with chitin deacetylases. 
Techniques  for  further  purification  of  CHOS  as  well  as  for  sequence  determination  are  now 
available, but are still quite challenging to exploit. Scaling up purification methods at an economically 
acceptable cost is another challenge, meaning that, from an economical point of view, it is probably 
cheaper to produce CHOS mixtures that are enriched for a bioactivity, rather than producing truly pure 
compounds.  It  is  conceivable  that  the  further  development  of  CHOS  as  bioactive  molecules  may 
include  further  functionalization  by  chemical  methods,  for  example  by  coupling  groups  to  the  
reducing end. 
These improved methods for producing (almost) pure, well-characterized CHOS will help to create 
a knowledge base for understanding how CHOS exert bioactivities. For example, it may soon be 
possible  to  determine  the  crystal  structures  of  chitinases  in  complex  with  a  CHOS  acting  as  an 
inhibitor. Likewise, the interaction of CHOS with AMCase [183] or HCgp39 [184] may be assessed by 
structural studies. 
CHOS have a remarkably wide spectrum of possible bioactivities. While highly promising, there is 
no doubt that these bioactivities need to be substantiated by further studies with well-defined CHOS 
preparations, as well as by fundamental research on the molecular mechanism behind the activity. 
Only then the great promise of converting an abundant bioresource, chitin, to CHOS-based medicines 
can be met. 
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